Knockdown of HNF1A improves type 2 diabetes combined with non-alcoholic fatty liver and glucose and lipid metabolism disorders by modulating the PI3K/AKT/mTOR signaling pathway

Non-alcoholic fatty liver disease (NAFLD) is one abnormal buildup of fat within the liver, independent of excessive alcohol intake. In type 2 diabetes, the presence of NAFLD can exacerbate chronic kidney diseases and mortality in patients. Hepatocyte nuclear factor 1 homeobox A (HNF1A) predominantly expressed in the liver, owns one crucial role in liver development, function and tumorigenesis. However, the precise regulatory role of HNF1A on the progression of type 2 diabetes combined with NAFLD keep dimness. This investigation uncovered that HNF1A levels, both in protein and mRNA expressions, were elevated in high-fat diet plus hyperglycemia (HFG) mice. Furthermore, liver steatosis was strengthened in the HFG group, which was mitigated following the HNF1A inhibition. Knockdown of HNF1A ameliorated glucose and lipid metabolism disorders in HFG mice. Lastly, the study observed an stimulation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in HFG mice, but this change was neutralized uponHNF1A silencing. In conclusion, knockdown of HNF1A improved type 2 diabetes combined with NAFLD, as well as disorders in glucose and lipid metabolism, and retarded the PI3K/AKT/mTOR signaling pathway. These finding demonstrated that HNF1A may be one serviceable target for ameliorating type 2 diabetes combined with NAFLD.

Type 2 diabetes; HNF1A; Non-alcoholic fatty liver; PI3K/AKT/mTOR pathway

[1] Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. International Journal of Molecular Sciences. 2022; 23: 15489.

[2] Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2022; 7: 851–861.

[3] Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nature Reviews Gastroenterology & Hepatology. 2023; 20: 487–503.

[4] Isaacs S. Nonalcoholic fatty liver disease. Endocrinology and Metabolism Clinics of North America. 2023; 52: 149–164.

[5] Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. Journal of Clinical Medicine. 2022; 11: 968.

[6] Chew NWS, Pan XH, Chong B, Chandramouli C, Muthiah M, Lam CSP. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population. Diabetes Research and Clinical Practice. 2024; 211: 111652.

[7] Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. Journal of the American Society of Nephrology. 2000; 11: S140–S143.

[8] Kalisz M, Bernardo E, Beucher A, Maestro MA, Del Pozo N, Millán I, et al. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer. The EMBO Journal. 2020; 39: e102808.

[9] Ng NHJ, Ghosh S, Bok CM, Ching C, Low BSJ, Chen JT, et al. HNF4A and HNF1A exhibit tissue specific target gene regulation in pancreatic beta cells and hepatocytes. Nature Communications. 2024; 15: 4288.

[10] Lau HH, Ng NHJ, Loo LSW, Jasmen JB, Teo AKK. The molecular functions of hepatocyte nuclear factors—in and beyond the liver. Journal of Hepatology. 2018; 68: 1033–1048.

[11] He J, Du C, Peng X, Hong W, Qiu D, Qiu X, et al. Hepatocyte nuclear factor 1A suppresses innate immune response by inducing degradation of TBK1 to inhibit steatohepatitis. Genes & Diseases. 2023; 10: 1596–1612.

[12] Patitucci C, Couchy G, Bagattin A, Cañeque T, de Reyniès A, Scoazec JY, et al. Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription. The Journal of Clinical Investigation. 2017; 127: 1873–1888.

[13] Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell. 1996; 84: 575–585.

[14] Li LM, Jiang BG, Sun LL. HNF1A: from monogenic diabetes to type 2 diabetes and gestational diabetes mellitus. Frontiers in Endocrinology. 2022; 13: 829565.

[15] Ye JH, Chao J, Chang ML, Peng WH, Cheng HY, Liao JW, et al. Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Scientific Reports. 2016; 6: 33102.

[16] Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments. Nature reviews. Gastroenterology & Hepatology. 2021; 18: 599–612.

[17] Li R, Ye Z, She D, Fang P, Zong G, Hu K, et al. Semaglutide may alleviate hepatic steatosis in T2DM combined with NFALD mice via miR-5120/ABHD6. Drug Design, Development and Therapy. 2022; 16: 3557–3572.

[18] Bao S, Wang X, Ma Q, Wei C, Nan J, Ao W. Mongolian medicine in treating type 2 diabetes mellitus combined with nonalcoholic fatty liver disease via FXR/LXR-mediated P2X7R/NLRP3/NF-κB pathway activation. Chinese Herbal Medicines. 2022; 14: 367–375.

[19] Li M, Zeng A, Tang X, Xu H, Xiong W, Guo Y. Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease. Scientific Reports. 2023; 13: 19807.

[20] Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes, Obesity & Metabolism. 2018; 20: 438–442.

[21] Ahmed YM, Abdelgawad MA, Shalaby K, Ghoneim MM, AboulMagd AM, Abdelwahab NS, et al. Pioglitazone synthetic analogue ameliorates streptozotocin-induced diabetes mellitus through modulation of ACE 2/Angiotensin 1–7 via PI3K/AKT/mTOR signaling pathway. Pharmaceuticals. 2022; 15: 341.

[22] Bathina S, Gundala NKV, Rhenghachar P, Polavarapu S, Hari AD, Sadananda M, et al. Resolvin D1 ameliorates nicotinamide-streptozotocin-induced type 2 diabetes mellitus by its anti-inflammatory action and modulating PI3K/Akt/mTOR pathway in the brain. Archives of Medical Research. 2020; 51: 492–503.

[23] Wang G, Zhang X, Zhou Z, Song C, Jin W, Zhang H, et al. Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway. Discover Oncology. 2023; 14: 4.

[24] Chen J, Chen J, Huang J, Li Z, Gong Y, Zou B, et al. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway. Aging. 2019; 11: 10839–10860.

[25] Liu B, Deng X, Jiang Q, Li G, Zhang J, Zhang N, et al. Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS/P38/Nrf2 axis and PI3K/AKT/mTOR pathway in macrophages. Biomedicine & Pharmacotherapy. 2020; 125: 109895.